Скачать с ютуб Novel 3-D In Vitro Models for Studying Pancreatic Cancer Drug Response and Resistance в хорошем качестве

Novel 3-D In Vitro Models for Studying Pancreatic Cancer Drug Response and Resistance

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal disease with a rapid mortality. Therapeutic resistance to chemotherapy is one of the main causes of treatment failure and ultimately death. Therefore, effective preclinical models are essential for providing a translational bridge between in vitro and in vivo studies to make clinically relevant discoveries. Patient-derived organoids (PDOs) are complex, self-organizing structures cultured from tumor cells embedded in a 3-D extracellular matrix. They display the self-renewal capacities, heterogeneity, preserved architecture, drug response, and genetic landscape of the original tumor—highly resembling the patient’s phenotypic characteristics. PDO culture requires a complex medium composition with specific niche growth factors and sophisticated techniques, which can be time-consuming and expensive to prepare. In this webinar, methodologies and experimental approaches to develop PDOs and isogenic primary cell lines as well as a method for recapitulating primary cell line cultures to organoids are described. The usefulness of cell line organoids (CLOs) as 3-D PDAC models is highlighted; these models maintain similar phenotype, in vitro architecture, and transcriptomic signatures as their matched PDOs. Additionally, a method for modeling drug resistance in PDOs is presented to identify clinically relevant resistance mechanisms to cytotoxic therapies. These models provide a manageable, expandable in vitro resource for multiple downstream applications and analyses.